{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:27:13Z","timestamp":1791073633187,"version":"4.1.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Transiliac bone biopsies were obtained from 55 women treated with teriparatide or placebo for 12\u201324 months. We report direct evidence that modeling bone formation at quiescent surfaces was present only in teriparatide-treated patients and bone formation at remodeling sites was higher with teriparatide than placebo.<\/jats:p>\n               <jats:p>Introduction: Recombinant teriparatide [human PTH(1-34)], a bone formation agent for the treatment of osteoporosis when given once daily subcutaneously, increases biochemical markers of bone turnover and activation frequency in histomorphometry studies.<\/jats:p>\n               <jats:p>Materials and Methods: We studied the mechanisms underlying this bone-forming action of teriparatide at the basic multicellular unit by the appearance of cement lines, a method used to directly classify surfaces as modeling or remodeling osteons, and by the immunolocalization of IGF-I and IGF-II. Transiliac bone biopsies were obtained from 55 postmenopausal women treated with teriparatide 20 or 40 \u03bcg or placebo for 12\u201324 months (median, 19.8 months) in the Fracture Prevention Trial.<\/jats:p>\n               <jats:p>Results: A dose-dependent relationship was observed in modeling and mixed remodeling\/modeling trabecular hemiosteons. Trabecular and endosteal hemiosteon mean wall thicknesses were significantly higher in both teriparatide groups than in placebo. There was a dose-dependent relationship in IGF-II immunoreactive staining at all bone envelopes studied. The greater local IGF-II presence after treatment with teriparatide may play a key role in stimulating bone formation.<\/jats:p>\n               <jats:p>Conclusions: Direct evidence is presented that 12\u201324 months of teriparatide treatment induced modeling bone formation at quiescent surfaces and resulted in greater bone formation at remodeling sites, relative to placebo.<\/jats:p>","DOI":"10.1359\/jbmr.060314","type":"journal-article","created":{"date-parts":[[2006,6,5]],"date-time":"2006-06-05T15:34:04Z","timestamp":1149521644000},"page":"855-864","source":"Crossref","is-referenced-by-count":208,"title":["Teriparatide Increases Bone Formation in Modeling and Remodeling Osteons and Enhances IGF-II Immunoreactivity in Postmenopausal Women With Osteoporosis"],"prefix":"10.1093","volume":"21","author":[{"given":"Yanfei L","family":"Ma","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqiang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Donley","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Georges","family":"Ste-Marie","sequence":"additional","affiliation":[{"name":"CHUM Hopital Saint-Luc, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Christopher","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Bone Metabolism Unit, Creighton University, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail P","family":"Dalsky","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Marcus","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Fink","family":"Eriksen","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019385376300_bib1","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1172\/JCI111096","article-title":"Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss","volume":"72","author":"Parfitt","year":"1983","journal-title":"J Clin Invest"},{"key":"2024013019385376300_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel","year":"2001","journal-title":"JAMA"},{"key":"2024013019385376300_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11914-004-0017-z","article-title":"The elusive concept of bone quality","volume":"2","author":"Recker","year":"2004","journal-title":"Curr Osteoporos Rep"},{"key":"2024013019385376300_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","article-title":"Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling","volume":"20","author":"Riggs","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01625448","article-title":"hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses","volume":"1","author":"Reeve","year":"1991","journal-title":"Osteoporos Int"},{"key":"2024013019385376300_bib6","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1172\/JCI116273","article-title":"An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis","volume":"91","author":"Hodsman","year":"1993","journal-title":"J Clin Invest"},{"key":"2024013019385376300_bib7","first-page":"620","article-title":"A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis","volume":"82","author":"Hodsman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019385376300_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/jcem-67-4-741","article-title":"Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers","volume":"67","author":"Eastell","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019385376300_bib9","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2003-1703","article-title":"Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy","volume":"90","author":"Dobnig","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019385376300_bib10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ar.1092260402","article-title":"Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff's law: The bone modeling problem","volume":"226","author":"Frost","year":"1990","journal-title":"Anat Rec"},{"key":"2024013019385376300_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S8756-3282(02)00947-X","article-title":"Trabecular minimodeling in human iliac bone","volume":"32","author":"Kobayashi","year":"2003","journal-title":"Bone"},{"key":"2024013019385376300_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"2024013019385376300_bib14","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"2024013019385376300_bib15","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019385376300_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone mineral density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib17","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Teriparatide [recombinant human parathyroid hormone (1-34)] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib18","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1043-2760(01)00460-X","article-title":"Reconstructing the skeleton with intermittent parathyroid hormone","volume":"12","author":"Seeman","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"2024013019385376300_bib20","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/bmj.280.6228.1340","article-title":"Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial","volume":"280","author":"Reeve","year":"1980","journal-title":"BMJ"},{"key":"2024013019385376300_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.1992.tb02323.x","article-title":"Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone","volume":"37","author":"Bradbeer","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024013019385376300_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/8756-3282(93)90190-L","article-title":"Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaces","volume":"14","author":"Hodsman","year":"1993","journal-title":"Bone"},{"issue":"S1","key":"2024013019385376300_bib23","first-page":"S179","article-title":"PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S8756-3282(99)00220-3","article-title":"Anabolic effect of prostaglandin E2 on cortical bone of aged male rats comes mainly from modeling-dependent bone gain","volume":"25","author":"Yao","year":"1999","journal-title":"Bone"},{"key":"2024013019385376300_bib25","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1210\/endo.136.8.7628403","article-title":"Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells","volume":"136","author":"Dobnig","year":"1995","journal-title":"Endocrinology"},{"key":"2024013019385376300_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/jbmr.5650040321","article-title":"Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo","volume":"4","author":"Hock","year":"1989","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling scheduling for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"2024013019385376300_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/(SICI)1097-0185(199609)246:1<39::AID-AR5>3.0.CO;2-A","article-title":"Trabecular and endocortical bone surfaces in the rat: Modeling or remodeling?","volume":"246","author":"Erben","year":"1996","journal-title":"Anat Rec"},{"key":"2024013019385376300_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4158\/EP.1.1.39","article-title":"Growth hormone, skeletal growth factors and osteoporosis","volume":"1","author":"Canalis","year":"1995","journal-title":"Endocr Pract"},{"key":"2024013019385376300_bib31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1172\/JCI0215463","article-title":"Circulating levels of IGF-1 directly regulate bone growth and density","volume":"110","author":"Yakar","year":"2002","journal-title":"J Clin Invest"},{"key":"2024013019385376300_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/153537020322800302","article-title":"From mouse to man: Redefining the role of insulin-like growth factor-I in the acquisition of bone mass","volume":"228","author":"Yakar","year":"2003","journal-title":"Exp Biol Med (Maywood)"},{"key":"2024013019385376300_bib33","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/endo-126-4-1806","article-title":"Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis","volume":"126","author":"Canalis","year":"1990","journal-title":"Endocrinology"},{"key":"2024013019385376300_bib34","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2174\/1381612043383764","article-title":"The anabolic effects of GH\/IGF system on bone","volume":"10","author":"Kasukawa","year":"2004","journal-title":"Curr Pharm Des"},{"key":"2024013019385376300_bib35","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1359\/jbmr.1999.14.12.2150","article-title":"Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis","volume":"14","author":"Boonen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"2024013019385376300_bib37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol"},{"key":"2024013019385376300_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/edrv-7-4-379","article-title":"Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease","volume":"7","author":"Eriksen","year":"1986","journal-title":"Endocr Rev"},{"key":"2024013019385376300_bib39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib40","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/jbmr.5650101116","article-title":"Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats","volume":"10","author":"Ma","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024013019385376300_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/002215549704500215","article-title":"Embedding of bone samples in methymethacrylate: An improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry","volume":"45","author":"Reinhold","year":"1997","journal-title":"J Histochem Cytochem"},{"key":"2024013019385376300_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","article-title":"Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis","volume":"27","author":"Hodsman","year":"2000","journal-title":"Bone"},{"key":"2024013019385376300_bib43","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"2024013019385376300_bib44","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1210\/jc.2002-021988","article-title":"Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment","volume":"88","author":"Misof","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019385376300_bib45","volume-title":"Intermediary Organization of the Skeleton","author":"Frost","year":"1986"},{"key":"2024013019385376300_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/8756-3282(86)90681-2","article-title":"Kinetics of trabecular bone resorption and formation in hypothyroidism: Evidence for a positive balance per remodeling cycle","volume":"7","author":"Eriksen","year":"1986","journal-title":"Bone"},{"key":"2024013019385376300_bib47","first-page":"110","article-title":"Evidence that the inhibition of TE85 human bone cell proliferation by agents which stimulate cAMP production may in part be mediated by changes in the IGF-II regulatory system","volume":"1","author":"Mohan","year":"1991","journal-title":"Growth Regul"},{"key":"2024013019385376300_bib48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/eje.0.1500081","article-title":"Influence of fluor salts, hormone replacement therapy and calcitonin on the concentration of insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor-beta 1 in human iliac crest bone matrix from patients with primary osteoporosis","volume":"150","author":"Pepene","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2024013019385376300_bib49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s001980200000","article-title":"Biomechanics of bone: Determinants of skeletal fragility and bone quality","volume":"13","author":"Turner","year":"2002","journal-title":"Osteoporos Int"},{"key":"2024013019385376300_bib50","first-page":"209","article-title":"Size, structure and gender: Lessons about fracture risk","volume":"2","author":"Martin","year":"2002","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2024013019385376300_bib51","first-page":"2331","article-title":"Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: Relationship to age, menopause, bone turnover, bone volume, and circulating IGFs","volume":"83","author":"Seck","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019385376300_bib52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s002239900486","article-title":"Stimulation of bone formation in vivo by insulin-like growth factor-II in rats","volume":"63","author":"Ishibe","year":"1998","journal-title":"Calcif Tissue Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.060314","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/6\/855\/56480003\/5650210606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/6\/855\/56480003\/5650210606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:46:31Z","timestamp":1710341191000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/21\/6\/855-864\/7593353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2006,6,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.060314","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,6,1]]},"published":{"date-parts":[[2006,6,1]]}}}